Tofacitinib versus Vedolizumab Among Bio-na&#xef;ve Patients with Ulcerative Colitis: A Real-World Propensity-Weighted Comparison

Inflammatory Bowel Disease

Real-world comparison of the effectiveness of tofacitinib and ustekinumab in patients with ulcerative colitis: the TORUS study

Clin Gastroenterol Hepatol

Buisson A, Serrero M, Altwegg R, Guilmoteau T, Bouguen G, Nachury M, Amiot A, Vuitton L, Treton X, Caillo L, Pereira B, Fumery M

doi: 10.1016/j.cgh.2025.07.044

Inflammatory Bowel Disease

Real-world Effectiveness of Ustekinumab Versus Anti-TNF or Vedolizumab in Ulcerative Colitis: Induction and 12-Month Maintenance Results from the Prospective, Observational RUN-UC Study

J Crohns Colitis

Bokemeyer B, Plachta-Danielzik S, Gilman E, Howaldt S, Mohl W, Efken P, Ehehalt R, Kahl M, Krause T, Trentmann L, Lügering A, Schnoy E, Jochum C, Hartmann P, Schreiber S

doi: 10.1093/ecco-jcc/jjaf052

Further Publications

Efficacy and safety of vedolizumab in elderly and younger patients with moderate-to-severe ulcerative colitis: a retrospective real-world study in China

BMC Gastroenterol

Zhang H, Ding XL, Xu YH, Wu J, Wang YY, Liu SX, Yan J, Liu H, Tian ZB, Liu AL

doi: 10.1186/s12876-025-04125-1

Inflammatory Bowel Disease

Effectiveness of Ustekinumab for patients with moderate to severe Ulcerative Colitis: A Multi-Center Real-World Canadian Study

Am J Gastroenterol

Solitano V, Narula N, Ma C, Nanayakkara A, Suarez KE, Zoughlami A, Guizzetti L, Bessissow T, Jairath V

doi: 10.14309/ajg.0000000000003212

Inflammatory Bowel Disease

Comparative effectiveness of tofacitinib versus upadacitinib for the treatment of acute severe ulcerative colitis

Clin Gastroenterol Hepatol

Honap S, St-Pierre J, Colwill M, Patel K, Le Berre C, Caron B, Nogami A, Kobayashi T, Altwegg R, Laharie D, Hebuterne X, Nachury M, Roblin X, Uzzan M, Kotze PG, Lukáš M, Vieujean S, D'Amico F, Albshesh A, Guillo L, Fumery M, Nancey S, Ye BD, Bergemalm D, Halfvarson J, Buisson A, Karmiris K, Rubin D, Vicaut E, Peyrin-Biroulet L, ATTRACT Study Group

doi: 10.1016/j.cgh.2025.07.025

Inflammatory Bowel Disease

Impact of Type 2 Diabetes on Clinical Outcomes and Advanced Therapy Use in Patients with Crohn's Disease: a Real-World Propensity Score-Matched Analysis

J Crohns Colitis

Massironi S, Solitano V, Furfaro F, D'Amico F, Zilli A, Allocca M, Peyrin-Biroulet L, Jairath V, Danese S

doi: 10.1093/ecco-jcc/jjaf157

Inflammatory Bowel Disease

Long-term safety of vedolizumab in patients with ulcerative colitis/Crohn's disease: A prospective observational study

Clin Gastroenterol Hepatol

Louis E, Sebastian S, Siegmund B, Bossuyt P, Danese S, de Boer N, Loftus EV, Moum B, Peyrin-Biroulet L, Schreiber S, Zhou J, Angellotti E, Adsul S, Jones S, Siegel CA

doi: 10.1016/j.cgh.2025.10.006

Inflammatory Bowel Disease

Real-World Experience with Upadacitinib for Pediatric Acute Severe Ulcerative Colitis: An International Multicenter Retrospective Study from the Pediatric IBD Porto Group of ESPGHAN

Inflamm Bowel Dis

Yerushalmy-Feler A, Spencer EA, Bergstein S, Mitrova K, Hradsky O, Bramuzzo M, Wlazlo M, Olbjørn C, Rungoe C, Weil N, Turner D, Cohen S

doi: 10.1093/ibd/izaf166

Inflammatory Bowel Disease

Acute severe ulcerative colitis patients from Asia have lower colectomy risk than patients from Australasia

Clin Gastroenterol Hepatol

Fernandes RG, Kim DH, Ruddick-Collins L, Vasudevan A, Brownson AR, Ngoi B, Lin CC, Haifer C, Kim DS, Swe E, Wright EK, Song EM, Mahy G, Moore GT, Lee HS, Kim HS, Zhang J, Yan Mak JW, Lee J, Lynch K, Gazelakis K, Rice K, Kim KO, Liu J, Lilian Bracken LM, Garg M, Schultz M, Clark N, Cao Q, Gilmore R, Park SH, Kim SJ, Sagami S, Wei SC, Kashkooli S, Schildkraut T, Lin WC, Hsu WH, Lee YJ, Kim ES, Begun J, Kobayashi T, An YK

doi: 10.1016/j.cgh.2025.10.019

Gastroenterology

Tofacitinib versus Vedolizumab Among Bio-naïve Patients with Ulcerative Colitis: A Real-World Propensity-Weighted Comparison

Related content

Real-world comparison of the effectiveness of tofacitinib and ustekinumab in patients with ulcerative colitis: the TORUS study

Real-world Effectiveness of Ustekinumab Versus Anti-TNF or Vedolizumab in Ulcerative Colitis: Induction and 12-Month Maintenance Results from the Prospective, Observational RUN-UC Study

Efficacy and safety of vedolizumab in elderly and younger patients with moderate-to-severe ulcerative colitis: a retrospective real-world study in China

Effectiveness of Ustekinumab for patients with moderate to severe Ulcerative Colitis: A Multi-Center Real-World Canadian Study

Comparative effectiveness of tofacitinib versus upadacitinib for the treatment of acute severe ulcerative colitis

Impact of Type 2 Diabetes on Clinical Outcomes and Advanced Therapy Use in Patients with Crohn's Disease: a Real-World Propensity Score-Matched Analysis

Long-term safety of vedolizumab in patients with ulcerative colitis/Crohn's disease: A prospective observational study

Real-World Experience with Upadacitinib for Pediatric Acute Severe Ulcerative Colitis: An International Multicenter Retrospective Study from the Pediatric IBD Porto Group of ESPGHAN

Acute severe ulcerative colitis patients from Asia have lower colectomy risk than patients from Australasia